Management of Anticoagulation After Gross Hematuria

Immediate Management

• Stop apixaban immediately when gross hematuria develops, as this represents active bleeding requiring urgent intervention 1, 2
• Do not use bridging anticoagulation with heparin or LMWH during the holding period, as this increases bleeding risk without reducing thrombotic complications 1, 2
• The short half-life of apixaban (approximately 12 hours) means anticoagulant effect will dissipate within 24-48 hours in patients with normal renal function 3

Duration of Hold Period

• Hold apixaban for 24-48 hours minimum after complete cessation of gross hematuria and confirmation of adequate hemostasis 1, 2
• For high-risk scenarios, extend the hold to 48-72 hours when bleeding was severe or required intervention 1, 2
• Patient is elderly (>80 years), as they have increased bleeding risk 1
• Significant renal dysfunction is present (CrCl <50 mL/min), which prolongs apixaban clearance 1, 3

Critical Decision Points Before Resumption

• No ongoing bleeding or clots on urinalysis before restarting apixaban 1
• Hemodynamic stability maintained before restarting apixaban 1
• No surgical contraindication to anticoagulation before restarting apixaban 1

Urologic Evaluation Imperative

• 25-30% of patients with anticoagulant-associated gross hematuria have significant urologic pathology, including malignancy in approximately 25% of cases 4, 5, 6

Resumption Strategy

• Resume apixaban at the patient's usual therapeutic dose—do not use reduced dosing unless there was a pre-existing indication for dose reduction 1, 2
• Therapeutic anticoagulation is restored within 3 hours of taking apixaban 3

Balancing Thrombotic vs Bleeding Risk

• The decision to resume anticoagulation must weigh the 22-29% risk of VTE recurrence in the first 3 months without therapy against the bleeding risk 4, 5, 6
• For atrial fibrillation patients, consider the stroke risk using CHA₂DS₂-VASc scoring when deciding timing of resumption 7
• The American Heart Association recommends considering the stroke risk when deciding the timing of anticoagulation resumption 7